GRFS News and Press, Grifols S.A. From 02/13/20

BARCELONA, Spain , Feb. 13, 2020 /PRNewswire/ --   Grifols (MCE:GRF, MCE:GRF.P NASDAQ:GRFS), a leading global producer of plasma-derived medicines and provider of technologies and services for hospitals, clinics and compounding centers, today announced that its PharmacyKeeper Verif...

On some levels, Rigel Pharmaceuticals (NASDAQ: RIGL) and Momenta Pharmaceuticals (NASDAQ: MNTA) are complete opposites. Rigel, based in South San Francisco, focuses on small molecule drugs while Momenta, headquartered in Cambridge, Massachusetts, tackles disease using large molecules cal...

Shares of Rigel Pharmaceuticals (NASDAQ: RIGL) rose as much as 14% today and have gained 35% in the last week. On Monday the company reported preliminary fourth-quarter and full-year 2019 operating results showing that its lead drug product, Tavalisse, could be back on a promising growth tra...

Foreword Any collection of stocks is more clearly understood when subjected to yield-based (dog catcher) analysis, these dividend-boosted batches are perfect for the Arnold dog catcher process. Here is your December 9 data from Barron's for 43 dividend-paying stocks supplemented by dog-c...

BARCELONA , Dec. 12, 2019 /PRNewswire/ --   Grifols (MCE:GRF, MCE:GRF.P NASDAQ:GRFS), a leading global producer of plasma-derived medicines, today announced the launch of its latest immunoglobulin (IG) innovation, XEMBIFY ® (immune globulin subcutaneous human-klhw), the compa...

Rigel Pharmaceuticals (NASDAQ: RIGL) developed and launched the drug Tavalisse for the treatment of the autoimmune disease called chronic immune thrombocytopenia (or immune thrombocytopenic purpura, "ITP"). In its first five quarters on the market, Tavalisse generated $44 million in net prod...

Investment Thesis CSL Limited ( CSLLY ) has become the second-largest company in the Australian Stock Exchange after an excellent run in the past twelve months, where its share price shot up ~54% compared to the ~18% gain in the S&P/ASX 200 index. A global leader in plasma fraction...

BARCELONA, Spain , Dec. 5, 2019 /PRNewswire/ --   Grifols   (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of technologies and services for hospitals, clinics and compounding centers, today announced the launch of its l...

Foreword Any collection of stocks is more clearly understood when subjected to yield-based (dog catcher) analysis, these dividend-boosted batches are perfect for the Arnold dog catcher process. Here is your November 18 data from Barron's for 58 dividend paying stocks supplemented by dog ca...

This article is part of a series that provides an ongoing analysis of the changes made to George Soros’s 13F stock portfolio on a quarterly basis. It is based on George Soros’s regulatory 13F Form filed on 11/14/2019. Please visit our Tracking Soros Fund Management Holdings ar...